Korean J Med.  2003 Jul;65(1):81-89.

Megadose CD34+ hemopoietic stem cell transplantation for patients with high risk acute myeloid leukemia who have no HLA matched donor: A pilot study of a full haplotype mismatch transplantation

Affiliations
  • 1Division of Hematology, Department of Internal Medicine, Catholic Hemopoietic Stem Cell Transplantation Center, The Catholic University of Korea College of Medicine, Seoul, Korea. cumckim@catholic.ac.kr

Abstract

BACKGROUND: Haploidentical transplantation has become a considerable clinical choice for acute myeloid leukemia (AML) patients lacking a HLA matched donor. We tried to reveal the possible role of a full haplotype mismatch transplantation.
METHODS
Four patients received stem cell transplantation from their full haplotype mismatched family donors. Conditioning regimen included total-body irradiation, intravenous busulfan, antithymocyte globulin, and fludarabine. Megadose transplants of CD34+ stem cells were in the range of 10.9 x 106/kg and 20.6 x 106/kg. Neither GvHD prophylaxis nor post-transplant G-CSF were given. We monitored patients' bone marrow cellularity and chimerism in the peripheral blood using real time PCR.
RESULTS
All patients showed stable engraftment. The most frequent side effect was severe mucositis, but all patients recovered successfully without early death. Nobody showed acute GvHD. Two refractory patients were relapsed early after transplantation. Other 2 patients have been in good clinical condition with follow-up duration of 1~4 months. CONCLSUION: We could overcome the main limitations-a GvHD and a graft failure- of a full haplotype mismatch transplantation with a newly developed conditioning regimen that might be used firstly according to review of literature. Although our study sample numbers and duration of follow-up are not enough yet, at least in patients who were in complete remission and categorized as high-risk AML, we suggest that this treatment modality should be considered actively.

Keyword

Full haplotype mismatch transplantation; High risk AML; GvHD; Graft failure

MeSH Terms

Antilymphocyte Serum
Bone Marrow
Busulfan
Chimerism
Follow-Up Studies
Granulocyte Colony-Stimulating Factor
Haplotypes*
Humans
Leukemia, Myeloid, Acute*
Mucositis
Pilot Projects*
Real-Time Polymerase Chain Reaction
Stem Cell Transplantation*
Stem Cells*
Tissue Donors*
Transplants
Antilymphocyte Serum
Busulfan
Granulocyte Colony-Stimulating Factor
Full Text Links
  • KJM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr